Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

摘要: Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin patients newly diagnosed glioblastoma. Patients Methods A total 41 adult (median Karnofsky performance status, 90%; median age, 56 years) were treated preirradiation TMZ at 150 mg/m 2 (1 week on/1 off), involved-field radiotherapy combined concomitant low-dose (50 ), maintenance starting using a schedule, (25 mg twice daily). Results The follow-up interval was 21.7 months. Grade 4 hematologic observed 15 (36.6%). Treatment-related nonhematologic 4-5 reported for (4.9%). progression-free survival 7.6 months (95% confidence interval, 6.2–10.4). 1-year rate 73.2% 56.8–84.2%). presence O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter methylation tumor tissue associated significantly superior survival. Conclusion dose-dense regimen resulted acceptable toxicity. Compared data from European Organization Research Treatment Cancer/National Cancer Institute Canada trial 26981-22981/CE.3, unmethylated MGMT appeared not to benefit intensifying regarding overall In contrast, are promising methylated promoter.